Literature DB >> 3924426

Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

K J Miller, R M McGovern, M M Ames.   

Abstract

Incubation of hexamethylmelamine for 1 h with human tumor cell lines in culture did not inhibit colony formation at concentrations up to the limit of drug solubility (200 micrograms/ml). When 1-h incubations were carried out in the presence of a 9,000 g rat liver supernatant preparation and an NADPH-generating system, hexamethylmelamine markedly reduced colony formation. Cyclophosphamide inhibition of colony formation was also dependent on the presence of a 9,000 g supernatant preparation and an NADPH-generating system in incubation mixtures. A 1-h incubation of N-methylolpentamethylmelamine (a DNA-alkylating metabolite formed during N-demethylation of hexamethylmelamine) with human tumor cell lines reduced colony formation in the absence of the liver-activating system. Substantial NADPH-dependent N-demethylation of hexamethylmelamine was observed with rat liver, lung, and kidney microsomal preparations. In contrast, little or no HMM metabolism was observed with tumor cells, tumor cell homogenates, or NADPH-fortified tumor cell microsomal preparations. NADPH-dependent formation of cytotoxic metabolites is a prerequisite for antiproliferative activity of hexamethylmelamine against these human tumor cell lines. In vivo activity of hexamethylmelamine against some tumors may require metabolism by normal cells and subsequent transport of active species to the tumor site.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924426     DOI: 10.1007/bf00257294

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Metabolism of hexamethylmelamine-ring-14C in rats and man.

Authors:  J F Worzalla; B D Kaiman; B M Johnson; G Ramirez; G T Bryan
Journal:  Cancer Res       Date:  1974-10       Impact factor: 12.701

2.  Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test.

Authors:  B N Ames; J Mccann; E Yamasaki
Journal:  Mutat Res       Date:  1975-12       Impact factor: 2.433

3.  Metabolic activation of hexamethylmelamine and pentamethylmelamine by liver microsomal preparations.

Authors:  M M Ames; M E Sanders; W S Tiede
Journal:  Life Sci       Date:  1981-10-12       Impact factor: 5.037

4.  N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine.

Authors:  A Gescher; M D'Incalci; R Fanelli; P Farina
Journal:  Life Sci       Date:  1980-01-14       Impact factor: 5.037

5.  Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine.

Authors:  T A Connors; A J Cumber; W C Ross; S A Clarke; B C Mitchley
Journal:  Cancer Treat Rep       Date:  1977-08

6.  Hexamethylmelamine. An evaluation of its role in the therapy of cancer.

Authors:  S S Legha; M Slavik; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

7.  Antitumor activity of cis-dichlorodiammineplatinum(II).

Authors:  M K Wolpert-DeFilippes
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  In vitro cytotoxicity of the methylmelamines.

Authors:  C J Rutty; G Abel
Journal:  Chem Biol Interact       Date:  1980-02       Impact factor: 5.192

9.  Parenteral formulation of hexamethylmelamine potentially suitable for use in man.

Authors:  M M Ames; J S Kovach
Journal:  Cancer Treat Rep       Date:  1982-07

10.  Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine.

Authors:  M M Ames; M E Sanders; W S Tiede
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

View more
  2 in total

Review 1.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.